{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-037994","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.876946+00:00","generated_at":"2026-06-12T07:44:18.556494+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kura Oncology Q2 net loss $37.2M; ziftomenib registration trial enrollment beats projections","bullets":["Q2 2023 net loss $37.2M vs $34.8M in Q2 2022; R&D expenses $28.2M (up from $24.3M).","Cash, equivalents & investments $477M at June 30, 2023; includes $93.6M net from June offering; runway to mid-2026.","Ziftomenib in NPM1-mutant AML: CR rate 35% at 600 mg RP2D; registration-directed trial (85 pts) enrollment ahead of projections.","Combination study KOMET-007 (ziftomenib + ven/aza or 7+3) now dosing patients; preliminary data expected Q4 2023 or Q1 2024.","Next-gen FTI KO-2806 Phase 1 FIT-001 trial to begin dosing in H2 2023; tipifarnib+alpelisib in HNSCC at highest planned dose cohort."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-037994","json":"https://secwatch.observer/filing/0000950170-23-037994.json","markdown":"https://secwatch.observer/filing/0000950170-23-037994.md","text":"https://secwatch.observer/filing/0000950170-23-037994.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000095017023037994/0000950170-23-037994-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000095017023037994/kura-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T07:44:18.556494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a556f12dd310c3204d4cf3f27126dbf02e398d1f","claim":"Kura Oncology, Inc. reported financial results for the second quarter ended June 30, 2023.","evidence_excerpt":"On August 3, 2023, Kura Oncology, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the second quarter ended June 30, 2023 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1422143/000095017023037994/0000950170-23-037994-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}